MENU

daniel kantor, md

Results that match your search are below

Filters

Content Type

Issue Year


Sort By:

Relevance Date

MS Minute: Late-Breaking Data From ECTRIMS—Evobrutinib Safety and Efficacy

A potential new first-in-class treatment affects Bruton's tyrosine kinase.

Daniel Kantor, MD, FAAN, FANA

MS Minute: Neuropsychologic Testing and Multiple Sclerosis

What is the value of neuropsychologic testing for patients with MS when there are often no available treatments?

Daniel Kantor, MD, FAAN, FANA

Multiple Sclerosis Minute

Overactive Bladder in MS

Functional imaging studies suggest neurogenic overactive bladder in people with MS may differ from idiopathic overactive bladder.

Daniel Kantor, MD, FAAN, FANA

Ms Minute

Update on CHANGE-MS: Clinical Trial Results for GNbAC1

Is the cause of MS within us?

Daniel Kantor, MD, FAAN, FANA

Ms Minute

New Guidelines for MS Treatment

Will new guidelines address variability in the care of patients with MS?

Daniel Kantor, MD, FAAN, FANA

Ms Minute

Advances from ACTRIMS

A single-track meeting creates more interaction opportunities that may lead to future advances.

Daniel Kantor, MD, FAAN, FANA

Ms Minute

Opportunities for Patients Arising From Practicalities of Health Care

Daniel Kantor, MD, FAAN, FANA

Ms Minute

Got a Minute for MS?

Daniel Kantor, MD, FAAN, FANA

Special Report

Multiple Sclerosis—The Truth Lies Within Us

Data presented at the recent ECTRIMS offer fresh insight and potentially new direction into the cause of multiple sclerosis.

Daniel Kantor, MD

Show More